Carbidopa abrogates L -dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2835-2844

  Wafa, Latif A ^a   Cheng, Helen ^a   Plaa, Nathan ^a   Ghaidi, Fariba ^a   Fukumoto, Takahiro ^b   Fazli, Ladan ^a   Gleave, Martin E ^a   Cox, Michael E ^a   Rennie, Paul S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

androgen receptor; carbidopa; L dopa decarboxylase; prostate cancer; tumor progression

Indexed keywords

ANDROGEN RECEPTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARBIDOPA; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DOPA DECARBOXYLASE; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; MICE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859633811     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26287     Document Type: Article

References (44)

1. Jemal A, Center MM, DeSantis C, Ward EM,. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-907.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ,. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. (Pubitemid 46148091)
3. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
4. Gleave M, Goldenberg SL, Bruchovsky N, Rennie P,. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1998; 1: 289-96. (Pubitemid 128545877)
5. Fleshner N,. Defining high-risk prostate cancer: current status. Can J Urol 2005; 12 Suppl 1: 14-7, discussion 94-6.
6. Petrylak DP,. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005; 65 (6 Suppl): 8-12. (Pubitemid 40804366)
7. Molina A, Belldegrun A,. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol, in press.
8. Dehm SM, Tindall DJ,. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-44. (Pubitemid 44435552)
9. Heemers HV, Tindall DJ,. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808. (Pubitemid 350294296)
10. Zhu ML, Kyprianou N,. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer 2008; 15: 841-9.
11. Wafa LA, Snoek R, Rennie PS,. Androgen receptor coregulators and their role in prostate cancer. In:, Tindall DJ, Mohler JL, eds. Androgen action in prostate cancer. New York: Springer, 2009. 341-74.
12. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM,. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007; 120: 719-33. (Pubitemid 46175390)
13. Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS,. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J 2003; 375 (Pt 2): 373-83. (Pubitemid 37315445)
14. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS,. Comprehensive expression analysis of l-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007; 38: 161-70. (Pubitemid 44880212)
15. Avgeris M, Koutalellis G, Fragoulis EG, Scorilas A,. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. Clin Biochem 2008; 41: 1140-9.
16. Margiotti K, Wafa LA, Cheng H, Novelli G, Nelson CC, Rennie PS,. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Mol Cancer 2007; 6: 38.
17. Gilbert J, Haber M, Bordow SB, Marshall GM, Norris MD,. Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. Am J Pathol 1999; 155: 17-21. (Pubitemid 29318697)
18. Jensen SM, Gazdar AF, Cuttitta F, Russell EK, Linnoila RI,. A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. Cancer Res 1990; 50: 6068-74. (Pubitemid 20331423)
19. Uccella S, Cerutti R, Vigetti D, Furlan D, Oldrini R, Carnevali I, Pelosi G, La Rosa S, Passi A, Capella C,. Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis. J Histochem Cytochem 2006; 54: 863-75. (Pubitemid 44106864)
20. Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A,. Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer 2010; 102: 1384-90.
21. Zhu MY, Juorio AV,. Aromatic L-amino acid decarboxylase: biological characterization and functional role. Gen Pharmacol 1995; 26: 681-96.
22. Di Stefano A, Sozio P, Iannitelli A, Cerasa LS,. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv 2009; 6: 389-404.
23. Poulopoulos M, Waters C,. Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core Evid 2009; 5: 1-10.
24. Diederich C, Milakofsky L, Hare TA, Hofford JM, Dadmarz M, Vogel WH,. Effects of L-DOPA/carbidopa administration on the levels of L-DOPA, other amino acids and related compounds in the plasma, brain and heart of the rat. Pharmacology 1997; 55: 109-16. (Pubitemid 27417418)
25. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS,. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 2006; 66: 10613-20. (Pubitemid 44799785)
26. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS,. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 2009; 15: 39-47.
27. Koshimura K, Tanaka J, Murakami Y, Kato Y,. Effects of dopamine and L-DOPA on survival of PC12 cells. J Neurosci Res 2000; 62: 112-9.
28. Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C,. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002; 277: 4609-17. (Pubitemid 34968489)
29. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW,. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 1998; 279: 1922-5. (Pubitemid 28168645)
30. Heemers HV, Regan KM, Schmidt LJ, Anderson SK, Ballman KV, Tindall DJ,. Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol 2009; 23: 572-83.
31. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L,. Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 1986; 181: 675-83. (Pubitemid 17230940)
32. Sun Y, Niu J, Huang J,. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009; 1: 148-62.
33. Gilbert JA, Frederick LM, Ames MM,. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 2000; 6: 4365-72.
34. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson CC, Gleave ME,. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007; 67: 10455-65. (Pubitemid 350070821)
35. Ippolito JE, Merritt ME, Backhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI,. Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proc Natl Acad Sci U S A 2006; 103: 12505-10. (Pubitemid 44267288)
36. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-15.
37. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Doria T, Buttyan R,. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162: 1800-5. (Pubitemid 29474732)
38. Alberti C,. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. G Chir 2011; 31: 568-74.
39. Deeble PD, Murphy DJ, Parsons SJ, Cox ME,. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001; 21: 8471-82. (Pubitemid 33108606)
40. Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK,. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 2009; 69: 12-23.
41. Yuan TC, Veeramani S, Lin MF,. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14: 531-47. (Pubitemid 350074046)
42. Wright ME, Tsai MJ, Aebersold R,. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003; 17: 1726-37. (Pubitemid 37072290)
43. Xie S, Lin HK, Ni J, Yang L, Wang L, di Sant'Agnese PA, Chang C,. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Prostate 2004; 60: 61-7. (Pubitemid 38669230)
44. Cox ME, Deeble PD, Lakhani S, Parsons SJ,. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 1999; 59: 3821-30. (Pubitemid 29381892)